Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
Arjun MajithiaDeepak L BhattAllon N FriedmanMichael MillerPhillippe Gabriel StegEliot A BrintonTerry A JacobsonSteven B KetchumRebecca A JulianoLixia JiaoRalph T DoyleCraig GranowitzMatthew J BudoffR Preston MasonJean Claude TardifWilliam E BodenChristie M BallantynePublished in: Circulation (2021)
In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01492361.